The Massachusetts Democrat is agreeing to back Bidenâs FDA pick after he put restrictions on the work heâd do and employment heâd seek.
www.politico.com
excerpts:
Robert Califf, who was first nominated more than two months ago, is agreeing to not seek employment or compensation from any pharmaceutical or medical device company that he interacts with âfor four yearsâ following his time in government, according to a letter he sent to the Massachusetts Democrat and obtained by POLITICO.
A spokesperson for Warren said that, should Califfâs nomination ultimately come to a vote, the Massachusetts Democrat plans to support him.
In the letter, Califf also agreed to a four-year period in which he will recuse himself from decisions before the agency related to companies with which he had relationships. Originally, the recusal period was two years.
an administration official defended Califfâs ethical track record, noting that he was confirmed by an 89-to-4 vote to lead the FDA during the Obama administration. At that time, Warren requested to see all research contracts between pharmaceutical companies and the Duke Clinical Research Institute founded by Califf. She subsequently voted for Califf.
The Massachusetts Democrat, who has pushed other Biden appointees to adopt stronger ethical standards, was among a handful of Democrats concerned by Califfâs $2.7 million paycheck for advising the Alphabet-owned Verily Life Sciences. That work, along with board seats Califf held on two other pharmaceutical companies, came after he served as FDA commissioner in the Obama administration.
Warrenâs support of Califfâs nomination doesnât ensure his confirmation. Califf has struggled to win the support of the 50 senators he needs amid concerns over his past ties to the drug industry and regulatory track record on opioids. Already, five Democrats in the evenly divided Senate have signaled theyâll oppose him â with others so far refusing to commit either way.
Just four Republicans, meanwhile, have publicly backed his candidacy. And according to three people with knowledge of the matter, Califf has also failed to impress some key senators in one-on-one meetings, further complicating his candidacy.
The lack of bipartisan support has increasingly alarmed Califfâs supporters, who privately blamed the White House in recent weeks for being too detached from the efforts to secure his confirmation. Already, the FDA has gone more than a year without a permanent leader, despite being at the center of Biden's Covid-19 response and vaccination campaign.